{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:45Z","timestamp":1792685985433,"version":"4.5.0"},"reference-count":22,"publisher":"Societas Neurologica Japonica","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2024]]},"DOI":"10.5692\/clinicalneurol.cn-002002","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T22:13:02Z","timestamp":1727302382000},"page":"708-713","source":"Crossref","is-referenced-by-count":1,"title":["Proposals for the early diagnosis of late-onset hereditary ATTR amyloidosis in \u200dnonendemic areas in Japan","\u65e5\u672c\u306e\u975e\u96c6\u7a4d\u5730\u306b\u304a\u3051\u308b\u9ad8\u9f62\u767a\u75c7\u907a\u4f1d\u6027ATTR\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u65e9\u671f\u8a3a\u65ad\u306e\u305f\u3081\u306e\u63d0\u8a00"],"prefix":"10.5692","volume":"64","author":[{"given":"Keiko","family":"Maruyama Saladini","sequence":"first","affiliation":[{"name":"Medical Affairs Division, Alnylam Japan K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Neurology &amp; Rheumatology, Shinshu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Sugimurakai Medical Association Sugimura Hospital"},{"name":"Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener 2014;3:19.","DOI":"10.1186\/2047-9158-3-19"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) \u95a2\u5cf6\u826f\u6a39\uff0e\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u6cbb\u7642\u306e\u9032\u6b69\uff0e\u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u96d1\u8a8c 2021;110:1170-1177.","DOI":"10.2169\/naika.110.1170"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31.","DOI":"10.1186\/1750-1172-8-31"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002;59:1771-1776.","DOI":"10.1001\/archneur.59.11.1771"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ueda M, Yamashita T, Misumi Y, et al. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Amyloid 2018;25:143-147.","DOI":"10.1080\/13506129.2018.1531842"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuro\u00adpathy. J Peripher Nerv Syst 2016;21:5-9.","DOI":"10.1111\/jns.12153"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Plante-Bordeneuve V. Transthyretin familial amyloid polyneuro\u00adpathy: an update. J Neurol 2018;265:976-983.","DOI":"10.1007\/s00415-017-8708-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Sekijima Y, Ueda M, Koike H, et al. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 2018;13:6.","DOI":"10.1186\/s13023-017-0726-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and \u200dtreatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag 2020;16:109-123.","DOI":"10.2147\/TCRM.S219979"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to \u200ddiagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 2022;93:668-678.","DOI":"10.1136\/jnnp-2021-327909"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Concei\u00e7\u00e3o I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 2019;26:3-9.","DOI":"10.1080\/13506129.2018.1556156"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Gillmore JD, Reilly MM, Coats CJ, et al. Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best practice in Ireland and the UK. Adv Ther 2022;39:2292-2301.","DOI":"10.1007\/s12325-022-02139-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 2022;29:143-155.","DOI":"10.1080\/13506129.2022.2052838"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Adams D, Ando Y, Beir\u00e3o JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021;268:2109-2122.","DOI":"10.1007\/s00415-019-09688-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nishi M, Takashio S, Morioka M, et al. Extracardiac biopsy sensitivity in transthyretin amyloidosis cardiomyopathy patients with positive <sup>99m<\/sup>Tc-labeled pyrophosphate scintigraphy findings. Circ J 2022;86:1113-1120.","DOI":"10.1253\/circj.CJ-22-0118"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Plant\u00e9-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003;40:e120.","DOI":"10.1136\/jmg.40.11.e120"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-186.","DOI":"10.1080\/13506120802193720"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of \u200dcardiac transthyretin amyloidosis. Circulation 2016;133:2404-2412.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-417.","DOI":"10.1016\/j.carpath.2016.07.001"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Vidal-Perez R, V\u00e1zquez-Garc\u00eda R, Barge-Caballero G, et al. Diagnostic and prognostic value of cardiac imaging in amyloidosis. World J Cardiol 2020;12:599-614.","DOI":"10.4330\/wjc.v12.i12.599"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Tozza S, Severi D, Spina E, et al. A compound score to screen patients with hereditary transthyretin amyloidosis. J Neurol 2022;269:4281-4287.","DOI":"10.1007\/s00415-022-11056-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Di Stefano V, Prinzi F, Luigetti M, et al. Machine learning for early diagnosis of ATTRv amyloidosis in non-endemic areas: a multicenter study from Italy. Brain Sci 2023;13:805.","DOI":"10.3390\/brainsci13050805"}],"container-title":["Rinsho Shinkeigaku"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/64\/10\/64_cn-002002\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T03:35:26Z","timestamp":1730518526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/64\/10\/64_cn-002002\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.cn-002002","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"cn-002002"}}